Jill Bates

626 total citations
30 papers, 363 citations indexed

About

Jill Bates is a scholar working on Geriatrics and Gerontology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Jill Bates has authored 30 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Geriatrics and Gerontology, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Hematology. Recurrent topics in Jill Bates's work include Pharmaceutical Practices and Patient Outcomes (10 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jill Bates is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (10 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Acute Myeloid Leukemia Research (3 papers). Jill Bates collaborates with scholars based in United States. Jill Bates's co-authors include Larry W. Buie, Kristy L. Richards, Nicole R. Pinelli, Lisa M. Holle, Eve M. Segal, Kamakshi V. Rao, Lindsey B. Amerine, Stephen F Eckel, Laurence J. Marton and Benjamín Frydman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biochemical Journal.

In The Last Decade

Jill Bates

29 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jill Bates United States 11 100 75 75 66 52 30 363
Scott W. Savage United States 13 133 1.3× 55 0.7× 78 1.0× 43 0.7× 73 1.4× 28 411
Greg Carney Canada 12 44 0.4× 75 1.0× 71 0.9× 118 1.8× 36 0.7× 37 620
Dorothee C. Dartsch Germany 11 111 1.1× 56 0.7× 25 0.3× 123 1.9× 35 0.7× 17 458
Welch United States 7 111 1.1× 104 1.4× 90 1.2× 55 0.8× 39 0.8× 13 530
Eve M. Segal United States 6 95 0.9× 58 0.8× 32 0.4× 18 0.3× 32 0.6× 13 243
Rolin L. Wade United States 15 45 0.5× 86 1.1× 52 0.7× 47 0.7× 23 0.4× 80 637
Sabrina W. Cole United States 10 111 1.1× 33 0.4× 52 0.7× 42 0.6× 52 1.0× 14 361
Alison Duffy United States 10 30 0.3× 63 0.8× 65 0.9× 94 1.4× 33 0.6× 25 338
Xiaomei Gu United States 12 193 1.9× 154 2.1× 24 0.3× 77 1.2× 26 0.5× 31 685
Justin Arnall United States 12 45 0.5× 75 1.0× 30 0.4× 64 1.0× 18 0.3× 46 333

Countries citing papers authored by Jill Bates

Since Specialization
Citations

This map shows the geographic impact of Jill Bates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jill Bates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jill Bates more than expected).

Fields of papers citing papers by Jill Bates

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jill Bates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jill Bates. The network helps show where Jill Bates may publish in the future.

Co-authorship network of co-authors of Jill Bates

This figure shows the co-authorship network connecting the top 25 collaborators of Jill Bates. A scholar is included among the top collaborators of Jill Bates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jill Bates. Jill Bates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bates, Jill, et al.. (2024). Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans. Clinical Pharmacology & Therapeutics. 116(2). 390–396. 1 indexed citations
2.
Bates, Jill, et al.. (2023). Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar. American Journal of Health-System Pharmacy. 80(16). 1082–1089. 5 indexed citations
3.
Bates, Jill, Jeffrey Fudin, & Jai N. Patel. (2022). Integrating pharmacogenomics into precision pain management. Supportive Care in Cancer. 30(12). 10453–10459. 4 indexed citations
4.
Chanfreau‐Coffinier, Catherine, Sony Tuteja, Leland E. Hull, et al.. (2022). Drug–drug–gene interaction risk among opioid users in the U.S. Department of Veterans Affairs. Pain. 163(12). 2390–2397. 6 indexed citations
5.
6.
Roberts, Megan C., R. Ryanne Wu, Corrine I. Voils, et al.. (2021). Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) Clinical Program at Initial Test Sites. Pharmacogenomics. 22(17). 1121–1133. 12 indexed citations
7.
Bates, Jill, et al.. (2020). Value of Cancer Care Forum: Pharmacy Call to Action. 2 indexed citations
8.
Bates, Jill, et al.. (2020). An Evaluation of the Effect of Pharmacist-Led Comprehensive Chemotherapy Consultation Services on Outpatient Appointment Adherence. Journal of Managed Care & Specialty Pharmacy. 26(6). 723–727. 3 indexed citations
9.
Lyons, Kayley, Larry W. Buie, Jill Bates, et al.. (2020). A Study of Layered Learning in Oncology. UNC Libraries. 1 indexed citations
10.
Bates, Jill, Stephen M. Clark, Benyam Muluneh, et al.. (2019). Patient engagement in first cycle comprehensive chemotherapy consultation pharmacist services and impact on patient activation. Journal of Oncology Pharmacy Practice. 25(4). 896–902. 11 indexed citations
11.
Segal, Eve M., et al.. (2019). Demonstrating the value of the oncology pharmacist within the healthcare team. Journal of Oncology Pharmacy Practice. 25(8). 1945–1967. 52 indexed citations
12.
Bates, Jill, et al.. (2019). A chemotherapy privileging process for advanced practice providers at an academic medical center. Journal of Oncology Pharmacy Practice. 26(1). 116–123. 2 indexed citations
13.
Reeves, Brandi, et al.. (2018). A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. Journal of Oncology Pharmacy Practice. 25(7). 1692–1698. 4 indexed citations
14.
Muluneh, Benyam, Allison M. Deal, Joshua F. Zeidner, et al.. (2017). A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. Clinical Lymphoma Myeloma & Leukemia. 18(1). e13–e18. 9 indexed citations
15.
Bates, Jill, Larry W. Buie, Kayley Lyons, et al.. (2016). A Study of Layered Learning in Oncology. American Journal of Pharmaceutical Education. 80(4). 68–68. 27 indexed citations
16.
Buie, Larry W., et al.. (2014). Denosumab for the Management of Hypercalcemia of Malignancy in Patients With Multiple Myeloma and Renal Dysfunction. Clinical Lymphoma Myeloma & Leukemia. 14(6). e207–e211. 35 indexed citations
17.
Murray, Brian, Jill Bates, & Larry W. Buie. (2012). Impact of a new assay for measuring serum creatinine levels on carboplatin dosing. American Journal of Health-System Pharmacy. 69(13). 1136–1141. 8 indexed citations
18.
Bates, Jill, et al.. (2011). Management of Menorrhagia Associated with Chemotherapy‐Induced Thrombocytopenia in Women with Hematologic Malignancy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 31(11). 1092–1110. 19 indexed citations
19.
Bates, Jill. (2010). Quality and Safety in Pharmacy Practice. American Journal of Health-System Pharmacy. 67(24). 2125–2125. 1 indexed citations
20.
Mitchell, John L.A., Jill Bates, Benjamín Frydman, et al.. (2002). Antizyme induction by polyamine analogues as a factor of cell growth inhibition. Biochemical Journal. 366(2). 663–671. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott W. Savage Breakdown of academic impact, for papers by Greg Carney Breakdown of academic impact, for papers by Dorothee C. Dartsch Breakdown of academic impact, for papers by Welch Breakdown of academic impact, for papers by Eve M. Segal Breakdown of academic impact, for papers by Rolin L. Wade Breakdown of academic impact, for papers by Sabrina W. Cole Breakdown of academic impact, for papers by Alison Duffy Breakdown of academic impact, for papers by Xiaomei Gu Breakdown of academic impact, for papers by Justin Arnall
Rankless by CCL
2026